For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue-License | - | - | 0 | - |
| Total revenue | - | -650* | 0 | 1,300 |
| Research and development | 25,217 | 36,825* | 28,535 | 22,267 |
| General and administrative | 5,710 | 5,749* | 5,277 | 6,422 |
| Total operating expenses | 30,927 | 42,573* | 33,812 | 28,689 |
| Loss from operations | -30,927 | -43,223* | -33,812 | -27,389 |
| Gain related to transaction with acquirer | - | 0* | 0 | 0 |
| Interest expense | 3,509 | 2,713* | 3,181 | 3,141 |
| Interest income | 1,007 | 1,689* | 1,783 | 2,124 |
| Other income (expense), net | -12 | 57* | -46 | -246 |
| Total other expense | -2,514 | -967* | -1,444 | -1,263 |
| Loss before income tax expense | -33,441 | -44,191* | -35,256 | -28,652 |
| Provision for income taxes | 0 | -1* | 0 | 2 |
| Net loss | -33,441 | -44,190 | -35,256 | -28,654 |
| Basic EPS | -2.15 | -2.848 | -2.28 | -1.85 |
| Diluted EPS | -2.15 | -2.848 | -2.28 | -1.85 |
| Basic Average Shares | 15,585,000 | 15,515,000 | 15,478,000 | 15,468,000 |
| Diluted Average Shares | 15,585,000 | 15,515,000 | 15,478,000 | 15,468,000 |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)